Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Lactate Is a Reliable Predictor of ICU Length of Stay Following Ultra-radical Ovarian Cancer Surgery

SUSAN ADDLEY, MARK MCGOWAN, VIREN ASHER, ANISH BALI, SUMMI ABDUL, VICTORIA CULLIMORE, HARRIET CROSSLAND and ANDREW PHILLIPS
Anticancer Research April 2022, 42 (4) 1979-1986; DOI: https://doi.org/10.21873/anticanres.15676
SUSAN ADDLEY
Department of Gynaecological Oncology, Royal Derby Hospital, Derby, U.K.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: suziaddley@doctors.org.uk
MARK MCGOWAN
Department of Gynaecological Oncology, Royal Derby Hospital, Derby, U.K.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
VIREN ASHER
Department of Gynaecological Oncology, Royal Derby Hospital, Derby, U.K.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ANISH BALI
Department of Gynaecological Oncology, Royal Derby Hospital, Derby, U.K.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SUMMI ABDUL
Department of Gynaecological Oncology, Royal Derby Hospital, Derby, U.K.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
VICTORIA CULLIMORE
Department of Gynaecological Oncology, Royal Derby Hospital, Derby, U.K.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HARRIET CROSSLAND
Department of Gynaecological Oncology, Royal Derby Hospital, Derby, U.K.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ANDREW PHILLIPS
Department of Gynaecological Oncology, Royal Derby Hospital, Derby, U.K.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background/Aim: With a greater proportion of women with advanced ovarian cancer (AOC) successfully undergoing radical cytoreductive surgery, the demand on peri-operative resources - including intensive care (ICU) beds - is also on the rise. Extended post-operative ICU length of stay (LOS) confers increased patient morbidity and mortality. Several variables associated with prolonged ICU LOS following AOC surgery have been identified. We aimed to evaluate the predictive value of serum lactate levels. Patients and Methods: All patients undergoing ultra-radical surgery for AOC in a large cancer centre over a 34-month period between 2018-2021 were identified via the institution tumour registry. Data were collected retrospectively via electronic care and operating records; biochemistry, radiology, and histopathology databases. Results: In total, 63 patients were identified. Elevated intra-operative serum lactate levels were associated with significantly longer length of ICU post-operative stay. Longer time for hyperlactaemia to normalise following surgery also conferred significantly longer ICU, high dependency and total hospital LOS. Greater blood loss, higher surgical complexity and peritoneal carcinomatosis score, and longer operating time were associated with higher – and persistently elevated – peri-operative lactate levels. Conclusion: Serum lactate in the context of ultra-radical surgery for AOC represents an accessible and inexpensive marker with potential to not only reliably predict LOS, but also to serve as a dynamic prompt for early targeted intervention. Early recognition and correction of hyperlactaemia following AOC may reduce ICU LOS limiting both the resource pressure and patient morbidity/mortality sequelae.

Key Words:
  • Ovarian cancer
  • surgery
  • cytoreduction
  • ultra-radical
  • lactate
  • length of stay

At the time of diagnosis, >60% of patients with ovarian cancer have advanced disease (AOC) (1). Complete surgical cytoreduction, coupled with platinum-based chemotherapy, represents optimal management (2–4). Advances in anaesthesia, surgical technique, and critical care as well as the concentration of ovarian cancer services in specialist high-volume centres have enabled increasing proportions of women with AOC to successfully undergo ultra-radical surgery (5). The boundaries of such surgeries continue to expand evolving from pelvic debulking, to potentially incorporating multi-visceral resection, extensive peritoneal stripping and complete cytoreduction of disease sites previously deemed surgical stopping points such as peri-hepatic, diaphragmatic and cardio-phrenic lymphatic involvement (6–11). Because the incidence of AOC is highest in the post-menopausal population, the majority of patients have, in addition, multiple co-morbidities at the time of diagnosis (12). This combination of disseminated malignancy, surgical radicality, and poor performance status (PS) accounts for 21-36% of all women undergoing surgery for OC requiring post-operative intensive care (ICU) admission (12, 13).

ICU admission following ultra-radical surgery for AOC has implications for both patients and resource demand. Studies collectively report increased mortality in ovarian cancer patients admitted to intensive care post-operatively; further compounded if ICU length of stay (LOS) exceeds 5 days (12, 14–16). The intensive care unit is a specialised clinical area whose optimal running necessitates highly-trained multi-disciplinary staff and 1:1 critical-care nursing, and is provided at significant cost. Therefore, the ability to predict the need for post-operative ICU and identify those at risk of prolonged admission has value; It can be used to improve pre-operative patient counselling, guide peri-operative decision-making and facilitate targeted provision of level 3 care following surgery.

Currently, peri-operative patient risk assessment and ICU demand prediction most often derive from the pre-operative utilisation of validated prognostic scoring systems. Clinical observations, physiological and laboratory measures are combined in advance of surgery to generate and assign individualised patient risk scores as well as to predict morbidity and mortality (17). Such systems can, however, be complex, time-consuming, and may require expensive software to employ. Furthermore, they may fail to take account of the impact of intra-operative events on prognosis (17). To this direction, it has been shown that older patient age, hypoalbuminaemia as well as the intra-operative variables such as prolonged operating time, increased blood loss, higher volume fluid and blood-product resuscitation and concomitant bowel resection, independently associate with increased potential for peri-operative morbidity and significantly longer ICU stay (5, 14, 16, 18–21).

A biomarker of increasing interest in this context is serum lactate, a by-product of glycolysis and measure of end organ perfusion. Hyperlactaemia is well established as a prognostic indicator of poorer outcome in critical illness; with a higher lactate level and longer time to normalise conferring greater risk of death (22–24). In the surgical context – whilst a paucity of evidence exists pertaining to gynaecological oncology – a series of studies on cardiac surgery report elevation of lactate in the peri-operative period as significantly correlating with greater morbidity; increased ventilatory and inotropic requirements and extended length of hospital stay (25, 26). Cardiac surgery patients developing a hyperlactaemia have been shown to experience an 8-10-fold increase in peri-operative mortality (27, 28).

We aimed to consider the value of this parameter in cytoreductive surgery for AOC, evaluating intra-operative lactate as a potential predictor of prolonged ICU stay, as well as determining the impact of time taken for the post-operative resolution of hyperlactaemia on ICU duration of stay. Extrapolating from our hypothesis that raised lactate levels during AOC surgery, and the persistence of such, thereafter, confer an increased ICU LOS, morbidity, mortality, and resources, we searched for peri-operative factors significantly influencing this biochemical marker. Hence, we also explored the potential merit of serial lactate measurements during and after cytoreductive surgery as a reliable guide for both intra-operative decision-making and targeted peri-operative goal-directed therapies – aiming to promptly identify and resolve hyperlactaemia, achieving real-time modification of patient risk and anticipated LOS.

Patients and Methods

Ethics statement. The study was designed and undertaken as a retrospective single-centre investigative data analysis; with no patient identifiers disclosed, nor interventions actioned. Ethical approval was not required.

Patient population. All consecutive patients undergoing ultra-radical cytoreductive surgery for newly-diagnosed histologically-proven FIGO stage III/IV epithelial ovarian/tubal/primary peritoneal cancer within the Derby Gynaecological Cancer Centre (DGCC) University Hospitals of Derby and Burton (UHDB) NHS Foundation Trust over a 34-month period from June 2018-March 2021 were identified using a prospective institutional electronic tumour registry. The DGCC is a large cancer centre, managing all patients with gynaecological malignancy within a defined catchment area of the East Midlands region of the U.K. As all UK NHS patients receive free treatment, with limited private capacity for the management of AOC, our study cohort is likely representative of the wider UK population. Patients undergoing both primary (PDS) and delayed debulking surgery (DDS) following neo-adjuvant chemotherapy (NACT) at DGCC were included; whilst those not admitted directly from operating theatre to ICU and for whom peri-operative serum lactate levels were not available were excluded.

Methods. Integral to management of AOC within our centre is robust multi-disciplinary team (MDT) discussion of all patients to reach consensus on management. Standard approach to ultra-radical surgery entails extensive patient counselling with cancer nurse specialist (CNS) support; pre-operative anaesthetic assessment; surgery led by a minimum of two consultant gynaecological-oncology surgeons with experience of upper abdominal cytoreductive techniques; and anaesthesia performed by a consultant anaesthetic specialist in AOC surgery. Patients are admitted electively to ICU post-operatively, stepping down to ward-level care via high dependency (HDU). Peri-operative lactate levels and supportive care interventions, such as fluid management and inotropes, are undertaken or administered at the discretion of the anaesthetic, critical-care and surgical teams.

Patient baseline characteristics were captured from electronic care records and the UHDB Trust electronic cancer database populating a study proforma with the following demographic and clinical variables: age at surgery; body mass index (BMI); smoking status; and performance status (PS) as assigned at pre-operative anaesthetic review. Additional staging, intra- and post-operative data were retrieved from biochemistry and radiology reports, MDT meeting outcomes and operation notes on tumour type, grade, and stage, estimated intra-operative blood loss (EBL) and operating time. Surgical complexity (SCS), peritoneal carcinomatosis index (PCI) scores and level of cytoreduction achieved, as determined by lead surgeon, were also included in the data collection; with SCS >8 and PCI >20 denoting high complexity surgery and tumour volume (29, 30). Patient tracking records were accessed to calculate length of stay, sub-categorised into ICU, HDU and total in-hospital LOS. All peri-operative serum lactate results, measured in standard units of mmol/l, were retrieved for each patient, identifying both maximum intra-operative and end of surgery levels. A threshold of >2 mmol/l was used to define ‘hyperlactaemia’; and value of >/equal to 4 mmol/l further defined as ‘severe hyperlactaemia’ (23). Time for lactate to normalise post-operatively was calculated from available serial measurements. Post-operative complications were recorded and classified according to the Clavien-Dindo system; and all hospital re-admissions within 30 days of surgery captured (31).

Statistical analysis. Data were collated into frequencies or percentages for categorical variables. Continuous variables were presented as mean, median or range values. To determine the significance of results, odds ratios (ORs) with confidence intervals (CI) were calculated – setting CI at 95% and significance level at p<0.05, and univariate analysis of data performed.

Study outcome measures. The primary outcome of the study was to evaluate the relationship between intra-operative serum lactate and intensive care, high dependency and overall hospital length of stay. The secondary outcome measure was to evaluate the relationship between time for serum lactate to normalise post-operatively and intensive care, high dependency and overall hospital length of stay. The tertiary outcome was to identify peri-operative factors associated with significantly higher intra-operative serum lactate levels.

Results

Patient population. A total of 63 patients were identified for inclusion in the study – see Table I. Median age was 66.3 years (range=47.1-84.1 years). Among all patients, 20.6% (n=13) were aged >/equal to 75 years. Median body mass index (BMI) was 25.0 (18.8-42) kg/m2; with 14.3% (n=9) of the cohort having BMI >/equal to 35 kg/m2. Smokers accounted for 9.5% (n=6) of patients. A pre-operative performance status (PS) of >/equal to 2 was assigned to 17.5% (n=11). Serous carcinoma was the most common underlying histopathological diagnosis (n=60, 95.2%) and the majority of patients had radiologically defined stage IVb disease (n=33, 52.4%). Primary and delayed debulking surgery was performed in 31.7% (n=20) and 68.3% (n=43) of women, respectively. Mean SCS and PCI scores were 7 (2-16) and 17 (3-38), respectively. Average blood loss at ultra-radical surgery was 985 ml (range=200-3,000 ml). Rates of complete cytoreduction to R0 were 95.0% (n=19) for PDS and 97.7% (n=42) for DDS. Mean LOS for ICU, HDU and total hospital stay were 3104 (731-13,730) min, 6,330 (1,048-22,029) min and 16.0 (6-78) days respectively. A total of 39 patients (61.9%) experienced post-operative complications varying from grade I-V; the most prevalent being grade II (n=16, 25.4%). The rate of patients re-admitted within 30 days of surgery was 14.3% (n=9).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table I.

Patient population baseline characteristics.

Impact of maximum intra-operative serum lactate on length of stay, complication, and re-admission rates. All patients (n=63) developed an intra-operative hyperlactaemia of >2 mmol/l during surgery for AOC. The maximum serum lactate recorded for each patient was categorised according to severity of hyperlactaemia – either as remaining <4 mmol/l (n=41) or reaching >/equal 4 mmol/L (n=22). Comparative analysis demonstrated a maximum intra-operative lactate level equal to or exceeding 4 mmol/l – that is, development of severe hyperlactaemia – as conferring a significantly longer post-operative ICU LOS (p=0.01). No significant difference was demonstrated, however, between cohorts when comparing duration of both HDU and total hospital admission (p>0.05). Maximum intra-operative lactate had no impact on the likelihood of developing complications, or post-operative re-admission (p>0.05; Table II).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table II.

Impact of maximum intra-operative serum lactate on length of stay, complication and re-admission rates.

Impact of end of surgery serum lactate on length of stay, complication and re-admission rates. End of surgery serum lactate levels were also categorised as being either <4 mmol/l (n=43) or >/equal 4 mmol/l (n=20). Data demonstrated the persistence of severe hyperlactaemia on closing was associated with a significantly longer post-operative ICU stay (p=0.04). A higher end of surgery lactate had no, however, significant impact on HDU, total hospital LOS or rates of post-surgical complications, including re-admission (Table III).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table III.

Impact of end of surgery serum lactate on length of stay, complication and re-admission rates.

Impact of time for serum lactate to normalise post-operatively on length of stay, complication, and re-admission rates. Time for hyperlactaemia to normalise post-operatively was compared as taking either <1,500 min (n=35) or >/equal 1,500 min (n=28). A longer time for elevated lactate levels to resolve following surgery was associated with significantly longer LOS in both ICU (p<0.00001) and HDU (p=0.005), as well as increased duration of total inpatient admission (p=0.03). No significant difference according to this variable was demonstrated, however, regarding complication and re-admission rates (p>0.05; Table IV).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table IV.

Impact of time taken for serum lactate to normalise post-operatively on length of stay, complication and re-admission rates.

Impact of peri-operative factors on intra-operative serum lactate levels. Age, body mass index, smoking status and pre-operative patient performance status. The patient age, BMI, smoking status and pre-operative PS had no significant effect on maximal intra-operative, end of surgery lactate level or time taken for hyperlactaemia to resolve post-surgery (Table V).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table V.

Impact of peri-operative factors on intra-operative serum lactates and time to normalise post-operatively.

Surgical complexity score. When comparing patients assigned a low/intermediate SCS (n=39) versus high SCS (n=24), both the maximum intra-operative and end of surgery serum lactate levels were significantly higher if SCS was equal to, or exceeded, 8 (p=0.0005 and p=0.002 respectively). The time taken for lactate to return within normal limits following surgery was also significantly longer for the high surgical complexity cohort (p=0.0001; Table V).

Peritoneal carcinomatosis index score. The impact of PCI score on severity of intra-operative hyperlactaemia was compared, considering serum lactate values for those with PCI <20 (n=47) versus >/equal 20 (n=16). In the context of a higher PCI, both the maximum lactate reached during surgery and value at end of surgery were significantly higher (p=0.001); as was the time taken for such to correct in the post-operative period (p=0.006; Table V).

Surgical blood loss. The impact of estimated blood loss on intra-operative lactate was evaluated, comparing patients with EBL of <1,000 ml (n=37) with >/equal 1,000 ml (n=26). Greater surgical blood loss was associated with significantly higher maximum intra-operative serum lactate (p=0.009), end of surgery lactate (p=0.019) and longer time for hyperlactaemia to resolve (p=0.002; Table V).

Operating time. Peri-operative lactate results were compared according to operating time – categorising duration of surgery as either <8 h (n=44) or >/equal to 8 h (n=19). Prolonged ultra-radical surgery, exceeding 8 h, generated significantly higher intra-operative serum lactate levels – and was associated with an extended time for elevated levels to normalise (p=0.001; Table V).

Discussion

Our results have demonstrated that, in the context of ultra-radical debulking surgery for AOC, intra-operative serum lactate measurements reaching >/equal 4 mmol/l, persistence of severe hyperlactaemia to and beyond end of surgery and a time interval of >/equal 1,500 min for elevated lactate levels to return to normal range are all associated with significantly longer duration of ICU stay. Delayed resolution of a post-operative hyperlactaemia was also shown to correlate with both a significantly increased HDU and total inpatient LOS. Variables identified as influential on peri-operative lactate trend were SCS >/equal 8, PCI score >/equal 20, EBL >/equal 1,000 ml and operating time >/equal 8 h. Each parameter was associated with significantly higher lactate levels and longer time for serum values to return to within normal limits.

Attributed to a combination of patient age, a typically co-morbid state often exacerbated by the pathogenesis of AOC and radicality of abdomino-pelvic surgery required to achieve complete cytoreduction in advanced disease, patients with disseminated ovarian cancer are more likely to require post-operative ICU than those undergoing surgery for other gynaecological malignancies of equivalent stage (19). ICU admission following debulking surgery for AOC is associated with increased mortality; an increased 30-day mortality of 11-27% for ovarian cancer patients admitted to ICU post-operatively has been reported (14, 15, 21, 32, 33). A further negative impact on survival has been reported in association with ICU LOS >5 days or in the context of unplanned admission (12, 16). Evidence to date has identified a number of individual factors as reliable predictors of need for post-operative ICU support following surgery for AOC (5, 14, 16, 18–20, 23, 34). One such study of 255 patients reported age >60 years, serum albumin <3.5 g/dl and CA 125 >500 U/ml as all associated with significant greater likelihood of requiring ICU post-surgery; with hypoalbuminaemia remaining independently significant on multivariate analysis (p=0.005) (19). Intra-operative variables conferring increased ICU demand in AOC include tumour volume >6 cm, concomitant lymphadenectomy or bowel resection, fluid resuscitation in excess of 5,000 ml, sub-optimal debulking, as well as both duration of surgery exceeding 200 min and end of surgery later than 1,900 h (16, 19).

Our study expands on this current evidence base in addition identifying serum lactate and lactate trend as reliable predictors of postoperative ICU, HDU and total hospital LOS following AOC surgery. Physiological lactate homeostasis is achieved by balancing production from multiple sources, including skin, red blood cells, muscle, and gastro-intestinal tract, with hepato-renal clearance, maintaining normal serum levels below 2 mmol/l (23). Hyperlactaemia occurs, however, when this balance is tipped by either increased production, decreased clearance or both (23). Two distinct mechanisms of excess lactate production have been described. The first characterised by anaerobic glycolysis, triggered in all shock states and the second, perhaps less well understood, a non-hypoxic metabolic process insidiously occurring in defined patho-physiological states, including malignancy (23). A peri-operative hyperlactaemia driven by the above processes is common and may be further compounded by the impairment of hepatic clearance induced by intra-operative hypovolaemia, hypotension, and hypothermia (23–26). Common medications, including anti-epileptics, biguanides such as metformin, salicylates including aspirin, as well the anaesthetic agent propofol can also potentially exacerbate a hyperlactaemia (23). High circulating levels of serum lactate have been shown to reduce cardiac contractility as well as limit vascular responsiveness to inotropic intervention. Hence, a high peri-operative serum lactate represents both an indirect marker of underlying pathophysiological instability or stress and a direct potentiator of an increasingly refractory cycle of cardiovascular compromise explaining the significant increase in morbidity, need for cardio-respiratory support, LOS and overall mortality risk reported in surgical patients developing hyperlactaemia (17, 23–25, 27, 28). This understanding serves to support the value of serum lactate as a guide for peri-operative decision-making and targeted goal-directed therapies aiming to both identify and promptly correct hyperlactaemia, minimising the potential for a persistent hyperlactaemia state to establish and hence the additional patient morbidity, mortality, and resource demand.

To develop this concept of modifying peri-operative risk and ICU requirement through early and pro-active management of hyperlactaemia further, we identified other peri-operative variables, in addition to the patho-physiological drivers above, appearing to directly influence lactate levels and trend specific to the context of AOC cytoreduction. Our study demonstrated high SCS, PCI score, EBL, and prolonged operating time as all associated with a significantly increased likelihood of developing a prolonged hyperlactaemia during and after surgery. Whilst the surgical complexity and PCI scores correlating with achieving R0 are non-modifiable at the time of surgery, close communication with the anaesthetic team ensures surgeon awareness of intra-operative lactate pattern. A prolonged, refractory hyperlactaemia should prompt re-evaluation of appropriateness of ongoing pursuit of complete cytoreduction versus potential need to limit radicality – particularly in cases demanding high complexity surgery for large volume, multi-site disease; and in the context of co-morbid, frail patient. EBL and operating time represent potentially more readily modifiable factors. Appropriate triaging of surgeries to specialist high volume centres, performance by surgeons with experience of cytoreductive techniques, consideration of pre-operative single-bolus tranexamic acid, intra-operative attention to meticulous haemostasis, and consideration of ‘buddy-operating’ system to counter surgeon fatigue are all measures associated with minimising blood loss, maximising surgical efficiency and hence limiting potential for surgical stress to trigger a difficult to correct hyperlactaemia and the resultant sequelae (35).

Our paper has both strengths and limitations. We report on a representative cohort of patients with AOC undergoing standard surgical techniques and approach to post-operative management, enabling reliable extrapolation of study findings to other centres. Our study represents an element of novelty, contributing to a currently limited evidence-base pertaining to the value of peri-operative serum lactate levels in the ultra-radical setting. Our population size was, however, small; and data collected retrospectively risking underpowering, as well as potential for selection, information, and recall bias. Whilst univariate analysis usefully identified significant associations, we acknowledge that it fails to account for the impact of additional confounding variables on results. Hence, further multi-centre evaluation is warranted incorporating larger patient populations, multivariate analysis, as well undertaking both survival and cost analyses to generate more robust conclusions on the clinical merit of serum lactate as a predictor of both short and long-term risk, LOS and as a useful therapeutic target in the context of AOC cytoreductive surgery.

Conclusion

Our study demonstrated serum lactate as an accessible, inexpensive, and reliable predictor of increased ICU, HDU and total hospital LOS following cytoreductive surgery for AOC. Representing a potentially modifiable marker, we suggest that serial peri-operative lactate levels are of value in this setting, guiding targeted goal-directed therapy and informing intra-operative decision-making, with the potential to optimise patient outcomes and limit service demand through the early recognition and correction of hyperlactaemia.

Footnotes

  • Authors’ Contributions

    SA, AP: concept, literature review, data collection, statistical analysis, writing, editing. McMG, VC, HC: data collection. VA, AB, SA: editing.

  • Conflicts of Interest

    The Authors have no conflicts of interest to declare in relation to this study.

  • Received February 18, 2022.
  • Revision received March 7, 2022.
  • Accepted March 8, 2022.
  • Copyright © 2022 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

References

  1. ↵
    Ovarian cancer statistics, UK. Available at: http://www.cancerresearchuk.org/heath-professional/cancer-statistics/statistics-by-cancer-type/ovarian-cancer [Last accessed on December 20, 2021]
  2. ↵
    1. Cannistra SA
    : Cancer of the ovary. N Engl J Med 351(24): 2519-2529, 2004. PMID: 15590954. DOI: 10.1056/NEJMra041842
    OpenUrlCrossRefPubMed
    1. Ozols RF,
    2. Bundy BN,
    3. Greer BE,
    4. Fowler JM,
    5. Clarke-Pearson D,
    6. Burger RA,
    7. Mannel RS,
    8. DeGeest K,
    9. Hartenbach EM,
    10. Baergen R and Gynecologic Oncology Group
    : Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21(17): 3194-3200, 2003. PMID: 12860964. DOI: 10.1200/JCO.2003.02.153
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Bristow RE,
    2. Tomacruz RS,
    3. Armstrong DK,
    4. Trimble EL and
    5. Montz FJ
    : Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20(5): 1248-1259, 2002. PMID: 11870167. DOI: 10.1200/JCO.2002.20.5.1248
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Díaz-Montes TP,
    2. Zahurak ML and
    3. Bristow RE
    : Predictors of extended intensive care unit resource utilization following surgery for ovarian cancer. Gynecol Oncol 107(3): 464-468, 2007. PMID: 17765297. DOI: 10.1016/j.ygyno.2007.07.074
    OpenUrlCrossRefPubMed
  5. ↵
    1. Querleu D,
    2. Planchamp F,
    3. Chiva L,
    4. Fotopoulou C,
    5. Barton D,
    6. Cibula D,
    7. Aletti G,
    8. Carinelli S,
    9. Creutzberg C,
    10. Davidson B,
    11. Harter P,
    12. Lundvall L,
    13. Marth C,
    14. Morice P,
    15. Rafii A,
    16. Ray-Coquard I,
    17. Rockall A,
    18. Sessa C,
    19. van der Zee A,
    20. Vergote I and
    21. duBois A
    : European Society of Gynaecological Oncology (ESGO) guidelines for ovarian cancer surgery. Int J Gynecol Cancer 27(7): 1534-1542, 2017. PMID: 30814245. DOI: 10.1097/IGC.0000000000001041
    OpenUrlAbstract/FREE Full Text
    1. Fotopoulou C,
    2. Concin N,
    3. Planchamp F,
    4. Morice P,
    5. Vergote I,
    6. du Bois A and
    7. Querleu D
    : Quality indicators for advanced ovarian cancer surgery from the European Society of Gynaecological Oncology (ESGO): 2020 update. Int J Gynecol Cancer 30(4): 436-440, 2020. PMID: 32086362. DOI: 10.1136/ijgc-2020-001248
    OpenUrlFREE Full Text
    1. Elattar A,
    2. Bryant A,
    3. Winter-Roach BA,
    4. Hatem M and
    5. Naik R
    : Optimal primary surgical treatment for advanced epithelial ovarian cancer. Cochrane Database Syst Rev (8): CD007565, 2011. PMID: 21833960. DOI: 10.1002/14651858.CD007565.pub2
    OpenUrlCrossRefPubMed
    1. Eisenkop SM,
    2. Spirtos NM,
    3. Friedman RL,
    4. Lin WC,
    5. Pisani AL and
    6. Perticucci S
    : Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecol Oncol 90(2): 390-396, 2003. PMID: 12893206. DOI: 10.1016/s0090-8258(03)00278-6
    OpenUrlCrossRefPubMed
    1. Addley S,
    2. Morotti M,
    3. Pinelli C and
    4. Soleymani Majd H
    : Transdiaphragmatic resection of enlarged cardiophrenic lymph node during interval debulking surgery for advanced ovarian cancer. Gynecol Oncol Rep 37: 100807, 2021. PMID: 34381861. DOI: 10.1016/j.gore.2021.100807
    OpenUrlCrossRefPubMed
  6. ↵
    1. Addley S,
    2. Yao DS and
    3. Soleymani Majd H
    : Primary diaphragmatic closure following diaphragmatic resection and cardiophrenic lymph node dissection during interval debulking surgery for advanced ovarian malignancy. Gynecol Oncol Rep 36: 100744, 2021. PMID: 33763514. DOI: 10.1016/j.gore.2021.100744
    OpenUrlCrossRefPubMed
  7. ↵
    1. Ross MS,
    2. Burriss ME,
    3. Winger DG,
    4. Edwards RP,
    5. Courtney-Brooks M and
    6. Boisen MM
    : Unplanned postoperative intensive care unit admission for ovarian cancer cytoreduction is associated with significant decrease in overall survival. Gynecol Oncol 150(2): 306-310, 2018. PMID: 29929924. DOI: 10.1016/j.ygyno.2018.06.008
    OpenUrlCrossRefPubMed
  8. ↵
    1. Yao T,
    2. DeJong SR,
    3. McGree ME,
    4. Weaver AL,
    5. Cliby WA and
    6. Kumar A
    : Frailty in ovarian cancer identified the need for increased postoperative care requirements following cytoreductive surgery. Gynecol Oncol 153(1): 68-73, 2019. PMID: 30612784. DOI: 10.1016/j.ygyno.2018.12.025
    OpenUrlCrossRefPubMed
  9. ↵
    1. Leath CA 3rd.,
    2. Kendrick JE 4th.,
    3. Numnum TM,
    4. Straughn JM Jr.,
    5. Rocconi RP,
    6. Sfakianos GP and
    7. Lang JD Jr.
    : Outcomes of gynecologic oncology patients admitted to the intensive care unit following surgery: A university teaching hospital experience. Int J Gynecol Cancer 16(5): 1766-1769, 2006. PMID: 17009969. DOI: 10.1111/j.1525-1438.2006.00702.x
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Abbas FM,
    2. Sert MB,
    3. Rosenshein NB,
    4. Zahyrak ML and
    5. Currie JL
    : Gynecologic oncology patients in the surgical ICU. Impact on outcome. J Reprod Med 42(3): 173-178, 1997. PMID: 9109088.
    OpenUrlPubMed
  11. ↵
    1. Amir M,
    2. Shabot MM and
    3. Karlan BY
    : Surgical intensive care unit care after ovarian cancer surgery: an analysis of indications. Am J Obstet Gynecol 176(6): 1389-1393, 1997. PMID: 9215205. DOI: 10.1016/s0002-9378(97)70366-1
    OpenUrlCrossRefPubMed
  12. ↵
    1. Borthwick HA,
    2. Brunt LK,
    3. Mitchem KL and
    4. Chaloner C
    : Does lactate measurement performed on admission predict clinical outcome on the intensive care unit? A concise systematic review. Ann Clin Biochem 49(Pt 4): 391-394, 2012. PMID: 22715295. DOI: 10.1258/acb.2011.011227
    OpenUrlCrossRefPubMed
  13. ↵
    1. Iyer R,
    2. Gentry-Maharaj A,
    3. Nordin A,
    4. Burnell M,
    5. Liston R,
    6. Manchanda R,
    7. Das N,
    8. Desai R,
    9. Gornall R,
    10. Beardmore-Gray A,
    11. Nevin J,
    12. Hillaby K,
    13. Leeson S,
    14. Linder A,
    15. Lopes A,
    16. Meechan D,
    17. Mould T,
    18. Varkey S,
    19. Olaitan A,
    20. Rufford B,
    21. Ryan A,
    22. Shanbhag S,
    23. Thackeray A,
    24. Wood N,
    25. Reynolds K and
    26. Menon U
    : Predictors of complications in gynaecological oncological surgery: a prospective multicentre study (UKGOSOC-UK gynaecological oncology surgical outcomes and complications). Br J Cancer 112(3): 475-484, 2015. PMID: 25535730. DOI: 10.1038/bjc.2014.630
    OpenUrlCrossRefPubMed
  14. ↵
    1. Ruskin R,
    2. Urban RR,
    3. Sherman AE,
    4. Chen LL,
    5. Powell CB,
    6. Burkhardt DH 3rd. and
    7. Chen LM
    : Predictors of intensive care unit utilization in gynecologic oncology surgery. Int J Gynecol Cancer 21(8): 1336-1342, 2011. PMID: 21897266. DOI: 10.1097/IGC.0b013e31822d0ed0
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Kathiresan AS,
    2. Brookfield KF,
    3. Schuman SI and
    4. Lucci JA 3rd.
    : Malnutrition as a predictor of poor postoperative outcomes in gynecologic cancer patients. Arch Gynecol Obstet 284(2): 445-451, 2011. PMID: 20803205. DOI: 10.1007/s00404-010-1659-y
    OpenUrlCrossRefPubMed
  16. ↵
    1. Brooks SE,
    2. Ahn J,
    3. Mullins CD and
    4. Baquet CR
    : Resources and use of the intensive care unit in patients who undergo surgery for ovarian carcinoma. Cancer 95(7): 1457-1462, 2002. PMID: 12237914. DOI: 10.1002/cncr.10872
    OpenUrlCrossRefPubMed
  17. ↵
    1. Nichol AD,
    2. Egi M,
    3. Pettila V,
    4. Bellomo R,
    5. French C,
    6. Hart G,
    7. Davies A,
    8. Stachowski E,
    9. Reade MC,
    10. Bailey M and
    11. Cooper DJ
    : Relative hyperlactatemia and hospital mortality in critically ill patients: a retrospective multi-centre study. Crit Care 14(1): R25, 2010. PMID: 20181242. DOI: 10.1186/cc8888
    OpenUrlCrossRefPubMed
  18. ↵
    1. Foucher CD and
    2. Tubben RE
    : Lactic acidosis. 2021. PMID: 29262026.
    OpenUrlPubMed
  19. ↵
    1. Bullock B and
    2. Benham MD
    : Bacterial sepsis. 2021. PMID: 30725739.
    OpenUrlPubMed
  20. ↵
    1. Kim J,
    2. Wu A,
    3. Grogan T,
    4. Wingert T,
    5. Scovotti J,
    6. Kratzert W and
    7. Neelankavil JP
    : Frequency and outcomes of elevated perioperative lactate levels in adult congenital heart disease patients undergoing cardiac surgery. J Cardiothorac Vasc Anesth 34(10): 2641-2647, 2020. PMID: 32139342. DOI: 10.1053/j.jvca.2020.01.051
    OpenUrlCrossRefPubMed
  21. ↵
    1. O’Connor E and
    2. Fraser JF
    : The interpretation of perioperative lactate abnormalities in patients undergoing cardiac surgery. Anaesth Intensive Care 40(4): 598-603, 2012. PMID: 22813486. DOI: 10.1177/0310057X1204000404
    OpenUrlCrossRefPubMed
  22. ↵
    1. Maillet JM,
    2. Le Besnerais P,
    3. Cantoni M,
    4. Nataf P,
    5. Ruffenach A,
    6. Lessana A and
    7. Brodaty D
    : Frequency, risk factors, and outcome of hyperlactatemia after cardiac surgery. Chest 123(5): 1361-1366, 2003. PMID: 12740248. DOI: 10.1378/chest.123.5.1361
    OpenUrlCrossRefPubMed
  23. ↵
    1. Demers P,
    2. Elkouri S,
    3. Martineau R,
    4. Couturier A and
    5. Cartier R
    : Outcome with high blood lactate levels during cardiopulmonary bypass in adult cardiac operation. Ann Thorac Surg 70(6): 2082-2086, 2000. PMID: 11156124. DOI: 10.1016/s0003-4975(00)02160-3
    OpenUrlCrossRefPubMed
  24. ↵
    1. Aletti GD,
    2. Dowdy SC,
    3. Podratz KC and
    4. Cliby WA
    : Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer. Am J Obstet Gynecol 197(6): 676.e1-676.e7, 2007. PMID: 18060979. DOI: 10.1016/j.ajog.2007.10.495
    OpenUrlCrossRefPubMed
  25. ↵
    1. Jacquet P and
    2. Sugarbaker PH
    : Current methodologies for clinical assessment of patients with peritoneal carcinomatosis. J Exp Clin Cancer Res 15: 49-58, 1996.
    OpenUrl
  26. ↵
    1. Clavien PA,
    2. Barkun J,
    3. de Oliveira ML,
    4. Vauthey JN,
    5. Dindo D,
    6. Schulick RD,
    7. de Santibañes E,
    8. Pekolj J,
    9. Slankamenac K,
    10. Bassi C,
    11. Graf R,
    12. Vonlanthen R,
    13. Padbury R,
    14. Cameron JL and
    15. Makuuchi M
    : The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg 250(2): 187-196, 2009. PMID: 19638912. DOI: 10.1097/SLA.0b013e3181b13ca2
    OpenUrlCrossRefPubMed
  27. ↵
    1. Staudinger T,
    2. Stoiser B,
    3. Müllner M,
    4. Locker GJ,
    5. Laczika K,
    6. Knapp S,
    7. Burgmann H,
    8. Wilfing A,
    9. Kofler J,
    10. Thalhammer F and
    11. Frass M
    : Outcome and prognostic factors in critically ill cancer patients admitted to the intensive care unit. Crit Care Med 28(5): 1322-1328, 2000. PMID: 10834673. DOI: 10.1097/00003246-200005000-00011
    OpenUrlCrossRefPubMed
  28. ↵
    1. Azevedo LCP,
    2. Caruso P,
    3. Silva UVA,
    4. Torelly AP,
    5. Silva E,
    6. Rezende E,
    7. Netto JJ,
    8. Piras C,
    9. Lobo SMA,
    10. Knibel MF,
    11. Teles JM,
    12. Lima RA,
    13. Ferreira BS,
    14. Friedman G,
    15. Rea-Neto A,
    16. Dal-Pizzol F,
    17. Bozza FA,
    18. Salluh JIF,
    19. Soares M and Brazilian Research in Intensive Care Network (BRICNet)
    : Outcomes for patients with cancer admitted to the ICU requiring ventilatory support: results from a prospective multicenter study. Chest 146(2): 257-266, 2014. PMID: 24480886. DOI: 10.1378/chest.13-1870
    OpenUrlCrossRefPubMed
  29. ↵
    1. Collins A,
    2. Spooner S,
    3. Horne J,
    4. Chainrai M,
    5. Runau F,
    6. Bourne T,
    7. Moss EL,
    8. Davies Q,
    9. Chattopadhyay S and
    10. Bharathan R
    : Peri-operative variables associated with prolonged intensive care stay following cytoreductive surgery for ovarian cancer. Anticancer Res 41(6): 3059-3065, 2021. PMID: 34083298. DOI: 10.21873/anticanres.15089
    OpenUrlAbstract/FREE Full Text
  30. ↵
    1. Lundin ES,
    2. Johansson T,
    3. Zachrisson H,
    4. Leandersson U,
    5. Bäckman F,
    6. Falknäs L and
    7. Kjølhede P
    : Single-dose tranexamic acid in advanced ovarian cancer surgery reduces blood loss and transfusions: double-blind placebo-controlled randomized multicenter study. Acta Obstet Gynecol Scand 93(4): 335-344, 2014. PMID: 24428857. DOI: 10.1111/aogs.12333
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Anticancer Research: 42 (4)
Anticancer Research
Vol. 42, Issue 4
April 2022
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Lactate Is a Reliable Predictor of ICU Length of Stay Following Ultra-radical Ovarian Cancer Surgery
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
11 + 8 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Lactate Is a Reliable Predictor of ICU Length of Stay Following Ultra-radical Ovarian Cancer Surgery
SUSAN ADDLEY, MARK MCGOWAN, VIREN ASHER, ANISH BALI, SUMMI ABDUL, VICTORIA CULLIMORE, HARRIET CROSSLAND, ANDREW PHILLIPS
Anticancer Research Apr 2022, 42 (4) 1979-1986; DOI: 10.21873/anticanres.15676

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Lactate Is a Reliable Predictor of ICU Length of Stay Following Ultra-radical Ovarian Cancer Surgery
SUSAN ADDLEY, MARK MCGOWAN, VIREN ASHER, ANISH BALI, SUMMI ABDUL, VICTORIA CULLIMORE, HARRIET CROSSLAND, ANDREW PHILLIPS
Anticancer Research Apr 2022, 42 (4) 1979-1986; DOI: 10.21873/anticanres.15676
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patients and Methods
    • Results
    • Discussion
    • Conclusion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Tumor Budding Grade and T Stage as Recurrence Predictors of High-risk Stage II Colorectal Cancer
  • Pathologic Complete Response (pCR) in Patient With Myxofibrosarcoma Who Underwent Neoadjuvant Radiation Concurrent to Complementary and Alternative Medicine
  • Machine Learning Model to Guide Empirical Antimicrobial Therapy in Febrile Neutropenic Patients With Hematologic Malignancies
Show more Clinical Studies

Similar Articles

Keywords

  • ovarian cancer
  • surgery
  • cytoreduction
  • ultra-radical
  • lactate
  • length of stay
Anticancer Research

© 2025 Anticancer Research

Powered by HighWire